Eli Lilly to Open Lab in Philadelphia, QIAGEN to Acquire Parse Biosciences, Novartis Expands to North Carolina

ChristianaCare’s Cawley Center for Translational Cancer Research has unveiled a first-of-its-kind organoid core in a community cancer center program. The new laboratory facility within the Helen F. Graham Cancer Center & Research Institute grows and tests living, patient-derived tumor models, which give doctors and researchers a faster, more precise way to identify the therapies most likely to work for each patient. By growing living tumor models from cells of individual patients, researchers can test real-world drug responses and tailor treatments for them in new, innovative ways. Press release. 

ARC Innovation at Sheba Medical Center and Icahn School of Medicine at Mount Sinai (part of the Mount Sinai Health System in New York City) announced a three-year collaboration with NVIDIA to harness artificial intelligence for genomic discovery through the application of large language model technology. The initiative aims to pioneer the decoding of the majority of the human genome that remains poorly understood in order to unlock new pathways for disease prevention, diagnosis, and treatment. Over the three-year period, the project will be supported by significant investment from the participating organizations, with the goal of accelerating research that can ultimately benefit patients worldwide. Press release. 

EvE Bio’s pharmome data is now being integrated into the Drug Bank platform. EvE Bio is systematically testing a large collection of FDA-approved small‑molecule drugs against a wide range of human druggable targets, producing a comprehensive dataset of drug-target interactions. EvE Bio’s high-throughput process has been designed to produce a robust, verifiable datapoint for every potential interaction, whether active or inactive. Press release. 

Abselion has expanded its Amperia assay portfolio with the launch of its Tagged Protein Quantification Kit | His-tag and Tagged Protein Sensor | His-tag Quantification. The novel assay, developed with GenScript’s THE His Tag Monoclonal Antibodies, provides researchers with a ready-to-use solution for rapid, reliable measurement of His-tagged proteins. This launch marks a significant milestone in extending Amperia, beyond antibody and AAV assays, into the wider field of recombinant protein analysis, enabling researchers to generate high-quality data more quickly and dependably across expression, optimization, and development workflows. Press release. 

Evosep announced a new initiative aimed at solving one of Liquid Chromatography-Mass Spectrometry (LCMS)-based proteomics most persistent challenges: sample preparation. Building on its legacy of standardizing proteomics LC separation, Evosep is now expanding upstream to deliver robust and reproducible solutions for sample preparation enabling a new era of end-to-end standardization in proteomics. Press release.

GENFIT has entered a research collaboration with EVerZom to expand its Acute-On-Chronic Liver Failure research via exosome-based regenerative technology. GENFIT and EVerZom plan to run exploratory studies to assess efficacy for EViv in ACLF, with a clear decision point within 18 months on whether to advance into clinical development. Press release. 

AAX Biotech and ToxoTech are collaborating to advance next-generation biotherapeutics. The partnership applies AAX’s Seqitope platform in a new therapeutic area, expanding its use beyond antibody epitope mapping. The co-development study combines AAX Biotech’s proprietary Seqitope platform with ToxoTech’s expertise in biologic drug design to create novel biotherapeutic candidates with improved potency and precision. By applying Seqitope to optimize receptor recognition, the collaboration aims to generate novel variants with potential as treatments for neuromuscular and neurological indications. Press release. 

QIAGEN has entered into a definitive agreement to fully acquire Parse Biosciences. The acquisition will significantly expand QIAGEN’s sample technologies portfolio into the fast-growing single-cell sequencing market with highly scalable chemistry designed to power research involving up to millions and billions of cells. Parse’s scalable chemistry is also expected to accelerate growth in the QIAGEN Digital Insights bioinformatics business, enabling customers to generate, process, and interpret AI-driven single-cell data more efficiently and at greater scale. Press release. 

Evotec has sold the Just - Evotec Biologics Toulouse site to Sandoz. Sandoz will acquire 100% of Just - Evotec Biologics EU, plus an indefinite technology license to Evotec's continuous manufacturing platform technology for a payment of approximately $350 million in cash. The agreement includes additional license fees and development revenues including success-based milestones, adding up to more than $300 million in the coming years. With this acquisition, Sandoz will gain access to Evotec's proprietary platform for integrated development and advanced continuous manufacturing of biologics via an indefinite license. Press release. 

Form Bio and Weill Cornell Medicine are collaborating to apply gene editing to develop drugs that reduce Alzheimer's disease risk in patients carrying high-risk genetic variants. This multi-phase initiative represents a significant step toward addressing one of the strongest genetic drivers of Alzheimer's disease. Carriers of the APOE4 allele face a substantially higher likelihood of developing Alzheimer's, making it a critical target for intervention. Press release. 

SandboxAQ launched OpenCryptography.com, the first public database mapping cryptographic assets, weaknesses, and risks across the digital ecosystem. The free resource translates raw cryptographic findings into clear risk signals, helping security teams identify exploitable vulnerabilities and prioritize remediation. It also gives enterprises, researchers, and policymakers visibility into real-world cryptographic deployments across the internet, which will help with uncovering weaknesses, strengthening defenses, and modernizing for the post-quantum era. Press release. 

Biostate AI has partnered with Narayana Health to develop the first AI models specifically designed to predict cardiovascular disease in Indian populations. The partnership tackles what clinicians call the "Data Gap," the fact that virtually all cardiovascular risk algorithms were developed using European and American patient data, despite South Asians developing heart disease 5-10 years earlier than Western populations and presenting with different genetic and molecular patterns. This leads to missed diagnoses, late-stage detection, and preventable deaths. Press release. 

Harbour BioMed launched its first fully human Generative AI HCAb (Heavy Chain-Only Antibody) Model powered by its Hu-mAtrIxTM AI platform, built upon the Harbour Mice platform. The AI HCAb Model establishes a closed-loop workflow that integrates AI-driven sequence generation, design and screening, and wet-lab validation. This end-to-end process transforms antibody discovery from blind screening to AI-driven intelligent selection, dramatically improving efficiency and accuracy in antibody discovery. Press release. 

Capitainer launched Capitainer DIP70, a new volumetric device designed to simplify and standardize remote urine sampling. The device automatically collects two precisely metered 70 µL samples in dried format, allowing convenient and hygienic sampling at home or in clinical and research settings. The drying process allows samples to be shipped by regular mail without the need for cold chain logistics, while minimizing the risk of microbial growth and analyte degradation. This also is a cost-effective solution for decentralized studies, toxicology, internal medicine, and other research or clinical applications. Press release. 

Xpedite Diagnostics launched SwiftX Sepsis (Research Use Only), a DNA extraction solution that isolates microbial DNA directly from primary whole-blood samples without the need for culture enrichment. In sepsis research, sensitivity is critical, the abundance of human cells mask scarce microbial signals. SwiftX Sepsis overcomes this barrier through a proprietary cell-capturing chemistry specifically optimized for binding microbial cells within whole blood. This method enables reliable recovery bacterial and fungal targets even at concentrations below 10 CFU/mL, accelerating molecular detection and pathogen profiling of blood stream infections from the very first sample. Press release. 

Swarm Oncology announced a research collaboration with a leading U.S. hospital to advance the feasibility and manufacturing of research-scale Swarm-T cell preparations by using samples from patients treated in the clinic’s cancer vaccine studies. Swarm’s platform amplifies patients’ immune response to cancer vaccines, potentially offering a new path towards durable remission in solid cancers. Under the agreement, the collaborating clinic will provide patient blood samples together with immune response data, from cancer patients who have received its cancer antigen vaccination. Swarm will use these materials to assess the phenotypic and antigen-specific T cell responses and when appropriate, manufacture research scale products. Press release.